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Addition of PTK787/ZK 222584 can lower the dosage of
amsacrine to achieve equal amounts of acute myeloid
leukemia cell death
Alida C. Weidenaara, Hendrik J.M. de Jongea, Vaclav Fidlerb, Arja ter Elsta,
Tiny Meeuwsen-de Boera, Jenny Douwesa, Jessica C.A. Bouma-ter Steegea,
Karel Ha¨hlenc,d, Willem A. Kampsa and Eveline S.J.M. de Bonta
Acute myeloid leukemia (AML) is a disease with a poor
prognosis. It has been demonstrated that AML cells
express the vascular endothelial growth factors, VEGFA
and VEGFC, as well as kinase insert domain-containing
receptor (VEGFR2), the main receptor for downstream
effects, resulting in an autocrine pathway for cell survival.
This study investigates the role of the VEGFR inhibitor
PTK787/ZK 222584 in leukemic cell death, and the
possibility of an additional effect on cell death by a
chemotherapeutic drug, amsacrine. In three AML cell lines
and 33 pediatric AML patient samples, we performed total
cell-kill assays to determine the percentages of cell death
achieved by PTK787/ZK 222584 and/or amsacrine. Both
drugs induced AML cell death. Using a response surface
analysis, we could show that, in cell lines as well as in
primary AML blasts, an equal magnitude of leukemic cell
death could be obtained when lower doses of the more
toxic amsacrine were combined with low dosages of the
less toxic VEGFR inhibitor. This study shows that PTK787/
ZK 222584 might have more clinical potential in AML
when combined with a chemotherapeutic drug such
as amsacrine. In future, it will be interesting to study
whether the complications and the long-term effects of
chemotherapy can be reduced by lowering the dosages of
amsacrine, and by replacing it with other drugs with lower
toxicity profiles, such as PTK787/ZK 222584. Anti-Cancer
Drugs 19:45–54 c 2008 Wolters Kluwer Health | Lippincott
Williams & Wilkins.
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Introduction
The outcome of patients with acute myeloid leukemia
(AML) has improved owing to intensive chemotherapy
combined with a reduction in treatment-related mortal-
ity. The long-term disease-free survival, however, varies
between 13 and 44%, depending on age and cytogenetics;
therefore, new treatment strategies are still warranted
[1–3].
The level of vascular endothelial growth factor (VEGF)
A at time of diagnosis has been described to be an
independent prognostic factor for treatment outcome in
pediatric AML: high VEGFA levels in AML cells are
related to worse outcomes [4,5]. VEGFA is the prototype
of the VEGF family, a group of angiogenic proteins, and it
was originally cloned from the HL-60 cell line. It seemed
to be a potent stimulator of endothelial cell migration
and proliferation [6]. Differential splicing of exon 6
and/or exon 7 results in various isoforms: the 121- and the
165- amino-acid isoforms have the most potent activity
on endothelial cells [7]. In the meantime, six VEGFs are
described; VEGFA to VEGFF [8–12]. These proteins
bind with various binding abilities to two cell-surface
receptor families: the tyrosine kinase receptors
(VEGFRs) and the neuropilin (NRP) receptors. Three
VEGFRs have been identified, namely, VEGF receptor
(VEGFR1) (FMS-like tyrosine kinase 1, FLT1), VEGFR2
[kinase insert domain-containing receptor (KDR)] and
VEGFR3 (FLT4) [13–15]. Only two neuropilins (NRP1
and NRP2) have been described until now [16,17].
NRP1 seems to act as a coreceptor that enhances
VEGF165 binding to KDR on endothelial cells [18].
KDR is thought to be the main receptor for downstream
effects of VEGF, and its deletion in mice is lethal [19].
KDR is expressed not only in endothelial cells, in which
stimulation enhances the proliferation and differentiation
of endothelial cells, but also in AML cells [20]. In
response to KDR stimulation, intracellular signals are
transmitted, such as signaling via mitogen-activated
protein kinase, the phosphatidylinositol 3-kinase (PI3K/
Akt) cascades or via the signal transducers and activators
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of transcription pathway, resulting in leukemic cell
proliferation and cell survival [21–23]. Antiapoptotic
effects of VEGFC have also been described by FLT4
signaling in AML [24].
The production of VEGFA and VEGFC, as well as the
VEGFR expression by AML cells, resulted in the
knowledge that an autocrine pathway for cell survival
exists. Interference with the autocrine VEGF pathway by
the blockade of VEGF/VEGFR signaling might, therefore,
result in increased apoptosis in leukemic cells.
PTK787/ZK 222584 inhibits the phosphorylation of
VEGF receptor tyrosine kinases [25]; it not only exerts
its major effect on KDR (IC50 0.037 mmol/l), but it also
inhibits FLT1 (IC50 0.077mmol/l), FLT4 (IC50 0.64mmol/l)
and other tyrosine kinases such as PDGFR-b (IC50
0.58 mmol/l), c-kit (IC50 0.73 mmol/l) and c-Fms (IC50
1.4 mmol/l). The aim of this study was to gain more
insight into the effect of PTK787/ZK 222584 on cell
death in AML cell lines and primary AML cells.
Moreover, the additional effect of VEGFR inhibition on
cell death achieved by a conventional cytostatic drug such
as amsacrine was investigated.
Methods
Acute myeloid leukemia cell lines and primary acute
myeloid leukemia blasts
The cell lines HL-60, TF-1, THP-1 and K562 were
obtained from American Type Culture Collection
(Manassas, Virginia, USA), cultured in RPMI-1640
medium supplemented with penicillin/streptomycin and
10% fetal bovine serum (Hyclone, Logan, Utah, USA) for
HL-60, THP-1 and K562 cells and additionally supple-
mented with 1 ng/ml granulocyte monocyte colony
stimulating factor for TF-1. Before incubation with
amsacrine (Pfizer, Capelle aan den IJssel, The Nether-
lands) and/or PTK787/ZK 222584 (a kind gift from the
joint development project between Novartis Pharmaceu-
ticals, Basel, Switzerland and Schering AG, Berlin,
Germany), AML cell lines were serum starved overnight
in serum-free medium.
After getting written informed consent, primary AML
blast samples at diagnosis from pediatric AML patients
were obtained from the Dutch Childhood Oncology
Group (DCOG), The Hague, The Netherlands, in
accordance with the regulations and protocols of the
medical ethics committee. Diagnoses of AML were
confirmed at the laboratory of the DCOG. Table 1 [26]
summarizes the patient characteristics. Mononuclear
cells were separated by using Lymphoprep (Nycomed,
Oslo, Norway) density gradients, which had been
cryopreserved in liquid nitrogen until use. The cryopre-
served AML cells were thawed rapidly at 371C and
diluted in a 5 volume of normal calf serum, as described
previously [27]. The remaining blast cell population
contained >95% AML cells, and is referred to hereafter
as AML cells.
RNA extraction and RT-PCR
Total RNA was extracted by Trizol methods, following
the description of the manufacturer (Life Technologies,
Gibco/BRL, Grand Island, New York, USA). Complemen-
tary DNAs (cDNAs) were prepared by reverse transcrip-
tion at 371C, for at least 1 h, in a 20-ml reaction mixture
containing 2 mg of total RNA, random hexamers (Pfizer),
5 first-strand buffer, RNAsin and reverse transcriptase
(Gibco/BRL). cDNA was amplified in the presence of
primers, 10 buffer, 1.5mmol/l MgCl2, dNTPs and Taq
(Gibco/BRL). The mixture was amplified in a Perkin
Elmer apparatus with PCR cycle conditions specific for
the PCRs tested. The PCR product was analyzed by
electrophoresis in 1.5% agarose gel. Gels were stained
with ethidium bromide and photographed. Specific
primers for b2-microglobulin were sense (CCA GCA
GAG AAT GGA AAG TC) and antisense (GAT GCT
GCT TAC ATG TCT CG); PCR product: 260 bp; 22
cycles and annealing temperature 551C.
For VEGFA, sense (GAG TGT GTG CCC ACT GAG
GAG TCC AAC) and antisense (CTC CTG CCC GGC
TCA CCG CCT CGG CTT); PCR product: 177, 312,
384 bp; 35 cycles and annealing temperature of 551C were
used. The primers for VEGFA span the splice junctions,
enabling the amplified product of splice variants to be
separated electrophoretically.
For VEGFC, sense (AGG CTG GCA ACATAA CAG AGA
A) and antisense (TGTAAT TGG TGG GGC AGG TC),
PCR product 479 bp; 30 cycles and annealing tempera-
ture of 651C were used.
Table 1 Characteristics of pediatric AML patients
Characteristics
No. 33
Sex (male/female), n 22 : 11
Age at diagnosis, years 9 (0–16)
Leukocytes at diagnosis, 109/l 127.6 (7.5–355.0)












The characteristics (age, leukocytes and thrombocytes) are given as median
(range).
AML, acute myeloid leukemia; FAB, French American British [26].
No., number of patient samples.
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Fluorescence-activated cell sorting
KDR protein expression was measured with the mono-
clonal anti-VEGF receptor 2 mouse immunoglobulin
(IgG1) isotype (Sigma, St Louis, Missouri, USA), which
recognizes an internal epitope of the KDR protein. Cells
(0.5106) were washed and incubated for 15min at room
temperature, in phosphate-buffered saline (PBS). Sub-
sequently, the cells were incubated for 20min at 41C with
1.0 mg of monoclonal anti-VEGFR2 mouse IgG1 isotype or
with 1.0 mg of IgG1 isotype control (BD Biosciences, San
Jose, California, USA). Cells were washed with PBS and
incubated for 20min at 41C with phycoerythrin-conju-
gated rabbit-antimouse F(ab)2 fragments (DakoCytoma-
tion, Glostrup, Denmark). Phycoerythrin fluorescence
was measured on a FACScalibur flow cytometer (BD
Biosciences, Erembodegem, Belgium) and expressed as
median fluorescence intensity. The control cell line used
to standardize the KDR protein expression assay included
the KDR-negative cell line K562.
Cellular drug-resistance measurement using a total
cell-kill assay
For the cell lines, amsacrine (0.001–1 mg/ml) at different
concentrations, and/or the VEGFR inhibitor PTK787/ZK
222584 (5–100 mmol/l) at different concentrations, were
tested, both in 96-well microculture plates, in quad-
ruplicate. A total of 33 patient samples were studied for
the effect of the VEGFR inhibitor PTK787/ZK 222584
(5–100 mmol/l), amsacrine (1 mg/ml) or a combination of
those drugs. In two patient samples, combined testing
was impossible owing to the low cell number. In six
pediatric AML samples, more concentrations of
amsacrine (0.001–2 mg/ml) and/or PTK787/ZK 222584
(5–50 mmol/l) in quadruplicate were studied. The phar-
macological profile of PTK787/ZK 222584 shows inhibi-
tion of the VEGFreceptor tyrosine kinases. The strongest
inhibition is found against KDR (IC50 0.037 mmol/l); it
exhibits a weaker inhibition of FLT1 (IC50 0.077 mmol/l)
and FLT4 (IC50 0.64 mmol/l). At higher concentrations,
the VEGFR inhibitor also inhibits other kinases belonging
to the same class as the VEGFRs, the PDGFR-b, c-kit
and c-Fms [25]. The in-vitro cellular drug resistance of
the cell lines and patient samples (100 000 cells/well)
were assessed using a 3-day cell-culture assay, on the basis
of the principle that only viable cells would be able to
reduce MTT (5mg/ml in PBS), added to each well for
4 h, to a colored formazan product that could be measured
spectrophotometrically at 520 nm, as described earlier
[28]. The optical density (OD) in the MTT assay was
linearly related to the number of viable cells. Control
wells contained only leukemic cells, with culture media
without drugs, and blank wells contained only culture
media. Percentages of cell survival were calculated at each
drug concentration by the equation (mean OD treated
wells/mean OD control wells) 100%, after correcting for
the background found in the blank wells. The results
were considered evaluable if the control wells still
contained 70% or more leukemic cells [determined by
May–Grunwald–Giemsa (MGG) staining] after a 3-day
culture period. The mean OD of the control wells, after
correction for the background, at 3 days always exceeded
0.1 arbitrary units for valid results. The LC50 value (drug
concentration needed to kill 50% of the leukemic cells)
was used to compare the differences between patients
and/or various drugs combinations. LC50 value equation:
([% leukemic cell survival> 50%] – 50)/([% leukemic
cell survival> 50%] – [% leukemic cell survival< 50%])
(drug concentration when leukemic cell survival
< 50% – drug concentration when leukemic cell survival
> 50%)+(drug concentration when leukemic cell survi-
val> 50%) [28].
Statistical analysis
The purpose of the statistical analysis was to study the
relationships between the survival (S) (after correction
for background activity of media culture) and the
cytostaticum concentration (CC) and VEGFR inhibitor
concentration (VC). For this purpose we used a type of a
response surface analysis. The survival proportions (S)
were transformed into logits Y= log[S/(1 –S)], and
mixed-effects models were fitted to the data [29].
Y was considered as being a normally distributed response
variable; VC and CC were considered to be variables
defining the fixed-effects parameters of the model, and
replications entered the model as random intercepts.
For patient data, the model also included the random
effects due to patients.
The building of a model proceeded as follows. First, we
fitted separate models for VC without CC and for CC
without VC. These preliminary analyses were used to
look for suitable transformations for VC and CC, which
were as simple as possible and such that the model
assumptions were satisfied. On the basis of these
preliminary analyses, VC and CC were transformed into
V= log(VC+25) and C= log(CC+0.01). For the cell
lines HL-60, TF-1 and THP-1, datapoints numbering 4, 2
and 4, respectively, seemed to be outliers – with the
absolute value of standardized residuals exceeding 3 –
and it was decided to exclude these points from the
analysis. Fitting mixed-effects models with polynomials
in V and C and analyzing their interactions revealed that
the data are well described by the following: for the cell
line HL-60, the fourth-order polynomial in V, third-order
in C and the third-order in product terms (comprising 15
fixed-effects parameters); for the cell line TF-1, the
fourth-order polynomial in both variables and in product
terms (19 parameters) and for the cell line THP-1, by the
third-order polynomial in both variables and in product
terms (13 parameters). For patient cells, the best-fitting
model included eight fixed-effects parameters.
Next we proceeded to fit joint models in both
transformed variables. The best-fitting model was used
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Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
to determine isoboles, that is, concentration combina-
tions resulting in the same cell survival. Computations
were carried out in S-PLUS 6.2 software (Insightful,
Seattle, Washington, USA).
The Wilcoxon signed-rank test and the Spearman’s
rank-correlation test were used to compare differences
between groups.
Results
In leukemic cell lines the vascular endothelial growth
factor receptor inhibitor PTK787/ZK 222584 can
partially replace amsacrine, resulting in equal extent
of cell death
To investigate whether cell lines can be potential targets
for the VEGFR inhibitor PTK787/ZK 222584, we first
determined the expression of VEGFA, VEGFC and KDR.
THP-1, TF-1 and HL-60 expressed three splice variants
of VEGFA (121, 165 and 189 amino acids). In contrast to
VEGFA, only THP-1 cells showed mRNA production of
VEGFC (data not shown). Next we determined KDR
protein expression (Fig. 1). THP-1 showed the strongest
expression of KDR compared with the cell line K562,
whereas TF-1 cells were only slightly positive for KDR.
PTK787/ZK 222584 is a potent inhibitor of VEGF
receptor tyrosine kinases [25]; it inhibits VEGF-induced
phosphorylation, and its action can be abolished
by the addition of VEGFA. PTK787/ZK 222584 is most
potent against KDR, but it also has an effect on FLT1
and FLT4.
Direct effects of PTK787/ZK 222584 on the four
leukemic cell lines were determined. In a total cell-kill
assay, we demonstrated that the VEGFR inhibitor
induces cell death in all three cell lines, as shown in
Fig. 2a (LC50 values for HL-60: 27 mmol/l; TF-1:
49 mmol/l; THP-1: 24 mmol/l). Excellent cell survival was
seen in the KDR-negative cell line K562, demonstrating
that the cell death induced by PTK787/ZK 222584 at
identical concentrations was not a toxic effect.
As shown before by others, phosphorylation of KDR was
decreased dose-dependently when the inhibitor PTK787/
ZK 222584 was used in our system (data not shown) [25].
The topoisomerase inhibitor amsacrine is one of the drugs
used in AML treatment. For this experiment amsacrine
was chosen because of reproducible and moderate cell-
death results in all cell lines; with a drug resulting in
hardly 50% of cell death at full dose, as well as with a drug
resulting in massive cell death at the lowest concentra-
tion, it will be hard to show the additional effects of other
agents in vitro. Leukemic cell survival after incubation
with various concentrations of amsacrine is shown in
Fig. 2b. Our results clearly point out that all three cell









































FACS analysis of the kinase insert domain-containing receptor (KDR)
expression in the leukemic cell lines TF-1, THP-1, HL-60 and K562.
THP-1 showed the strongest expression of KDR compared with the
negative control cell line K562. HL-60 showed a weaker expression,
whereas TF-1 cells were only slightly positive for KDR. PE,
phycoerythrin.
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0.047mg/ml for HL-60, 0.207mg/ml for TF-1 and 0.067mg/ml
for THP-1.
To investigate the additional effects of VEGFR inhibition
on the cell death achieved by amsacrine, we combined
both drugs in a total cell-kill assay. A response surface
analysis was used, which emphasizes the finding of a
particular treatment combination that can evoke max-
imum or minimum responses. Figure 3 presents plots of
cell survival as a function of concentrations of both drugs.
For each cell line the raw data are displayed in the first
plot (Fig. 3a, d, g). The raw data are transformed into
predicted survival models, which are based on the best-
fitting models for the polynomials and parameters
(Fig. 3b, e, h). The raw data and the model-predicted
survival demonstrate, for each cell line, that when
increasing the concentration of one or both drugs, the
survival percentage of the AML cells will decrease. Next,
the best-fitting model was used to determine isoboles
(Fig. 3c, f, i). Isoboles estimate drug combinations that
result in the same survival; the lines in the figure
represent the drug combinations at which 30, 40, 50, 60
or 70% (0.3–0.7) cell survival will be achieved. For
example, for TF-1 Fig. 3c suggests that a 50% leukemic
cell survival (the line 0.5) can be achieved as follows: this
can be the result of amsacrine alone dosed at 0.15 mg/ml
or amsacrine at 0.12 mg/ml combined with 20 mmol/l PTK
or 0.03 mg/ml amsacrine combined with 80 mmol/l PTK.
Interestingly, the isoboles for each cell line point out that
the concentration of amsacrine can be lowered by a
certain dose of the potentially less toxic VEGFR inhibitor
PTK787/ZK 222584, to achieve the same percentage of
leukemic cell death.
PTK787/ZK 222584 increases cell death in primary
leukemic blasts when combined with amsacrine
Underscoring the results in the literature, KDR expres-
sion was demonstrated in all the AML samples tested
[30]. Figure 4 shows the LC50 values of the primary AML
samples with a median of 5.1 mmol/l (n=33). Primary
blast samples are overall 5–10-fold more sensitive to
PTK787/ZK 222584 than the leukemic cell lines used in
this study. Patients with an LC50 value above the median
did not differ from patients with an LC50 value below it,
with regard to age at diagnosis, sex, French American
British classification, leukocyte count or thrombocyte
count. Moreover, there was no relationship between
the expression of KDR in the patients we tested
and sensitivity to PTK787/ZK 222584 (Spearman’s
r= –0.63, P=0.825).
The next step was to test the addition of the VEGFR
inhibitor PTK787/ZK 222584 to amsacrine on the primary
AML blasts, and to determine the cell-death percentage
induced by both drugs (n=31). We first treated the
patient samples with 1 mg/ml amsacrine alone; we chose
1 mg/ml amsacrine because this concentration was near
the LC50 value of the patient samples. A varying
percentage of cell death was seen for 1 mg/ml amsacrine
alone, with a median value of 60.6%. Interestingly, we
found a correlation between the LC50 values of the
VEGFR inhibitor PTK787/ZK 222584 and the cell-death
percentages induced by 1 mg/ml amsacrine (Spearman’s
r= –0.386, P=0.032), which means that samples
sensitive to one drug are also sensitive to the other drug.
Two samples achieved a cell-death percentage of > 90%
and were excluded from further combination therapy,
because it was not possible to show additional effects of
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(a) Cell-survival percentages after incubation with the vascular
endothelial growth factor receptor (VEGFR) inhibitor PTK787/ZK
222584 were determined by using an MTT assay. The data indicates
that the VEGFR inhibitor induces cell death in all three cell lines.
HL-60 showed the strongest response, whereas TF-1 is least sensitive
to the VEGFR inhibitor. Values are expressed as means; bars, SE.
(b) Cell-survival percentages after incubation with amsacrine at
different concentrations were determined by using an MTT assay. The
data clearly indicates that amsacrine induces cell death in all three cell
lines. Values are expressed as means; bars, SE.
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Next, 29 patient samples were treated with 1 mg/ml
amsacrine and 25 mmol/l PTK787/ZK 222584, with a
median value of 92.3% cell death. Figure 5 demonstrates
the cell-death percentage achieved by 1 mg/ml amsacrine
with 25 mmol/l PTK787/ZK 222584 compared with the
cell-death percentage achieved by 1 mg/ml amsacrine
alone. The addition of 25 mmol/l PTK787/ZK 222584
resulted in an increase in cell death of > 20% (median
increase in cell death 24%) in 18 of the 29 samples (62%),
whereas 10 samples showed a moderate increase between
0–20%. No significant additional cell death was demon-
strated when PTK787/ZK 222584 dosage was increased
up to 100 mmol/l.
In addition, for six AML patient samples the combination
of amsacrine and PTK787/ZK 222584 treatment was
investigated more extensively to obtain isoboles for the
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Interaction data between the vascular endothelial growth factor receptor (VEGFR) inhibitor PTK787/ZK 222584 (PTK) and amsacrine for the three
acute myeloid leukemia cell lines. (a, d, g) Three-dimensional (3D) plots presenting the raw data for each cell line. (b, e, h) 3D plots presenting a
predicted model based on the raw data are demonstrated for all three cell lines. In these six figures, the vertical axis represents the (predicted)
survival of the cell line, estimated at different concentrations of both drugs (horizontal axes). These six plots show that increasing the concentration of
one or both drugs (in the figures named log amsacrine and log PTK) results in a decrease of the survival. (c, f, i) A model that can be used to calculate
drug combinations that result in a predicted survival, the so-called isoboles. The lines in these figures (shown as 0.3–0.7) represent the drug
combinations at which 30, 40, 50, 60 or 70% of cell survival will be achieved. All three figures point out that the concentration of amsacrine can be
lowered and replaced by a dose of the VEGFR inhibitor PTK787/ZK 222584, to achieve the same cell-death percentage. In the 3D plots, the
(transformed) PTK and amsacrine axes extend over the full range of values as used in the experiments, respectively, 0–50 and 0–2. The scale used in
the isobole plots differs per cell line.
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ZK 222584 and amsacrine for primary AML blasts is given
in Fig. 6. Again in Fig. 6a the raw survival data are
demonstrated, whereas Fig. 6b represents the model
predicted using the raw data. In Fig. 6c the isoboles are
shown. Identical to the results from the cell line, in
primary patient material also we were able to demonstrate
that lowering the concentration of the chemotherapeutic
drug amsacrine resulted in identical cell death, by adding a
certain dose of the potentially less toxic VEGFR inhibitor
PTK787/ZK 222584 to primary AML blasts.
Discussion
The results of this study show that PTK787/ZK 222584, a
VEGFR inhibitor, has potent in-vitro cell-death effects
against three AML cell lines and primary AML blasts.
Interestingly, we show that in a combined strategy, the
toxic amsacrine can be partially replaced by a potentially
less toxic VEGFR inhibitor, PTK787/ZK 222584, inducing
equal amounts of leukemic cell death in vitro not only in
cell lines but also in primary AML blasts.
VEGF/VEGFR signaling has been described in several
tumors such as multiple myeloma [31], melanoma [32]
and leukemia [33], resulting in proliferation and survival
of tumor cells. In our study we demonstrate that HL-60,
THP-1 and TF-1 do show expression of KDR and respond
to the VEGFR inhibitor PTK787/ZK 222584. The low
sensitivity of TF-1 might be the result of a low KDR
expression. The KDR-negative cell line K562 showed no
response to the VEGFR inhibitor PTK787/ZK 222584,
whereas K562 is positive for FLT1 and FLT4 [34,35]. In
all patient samples, we demonstrated high KDR expres-
sion, supporting recent results of others [30]. A relation-
ship between the expression of KDR and sensitivity for
PTK787/ZK 222584 was not found.
Recently, studies of other VEGFR inhibitors for the
treatment of AML were published. SU5416, a receptor
tyrosine kinase inhibitor of c-kit, FLT3 and KDR (IC50
0.20 mmol/l), induces growth arrest and apoptosis in AML
cells in vitro [36,37]. A phase 2 study of SU5416 in
































The LC50 value of 33 pediatric acute myeloid leukemia samples: the
concentration needed to kill 50% of the cells after incubation with the
vascular endothelial growth factor receptor inhibitor PTK787/ZK
222584. The bar represents the median value of 5.1mmol/l. In two
primary blast samples, the LC50 value was above 100mmol/l PTK787/
ZK 222584. Patients with an LC50 value above the median did not
differ from those with an LC50 value below the median with regard to
age at diagnosis, sex, French American British classification or white
blood cell count.
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The cell-death percentage achieved by 1mg/ml amsacrine combined
with 25mmol/l PTK787/ZK 222584 (PTK) compared with that
achieved by 1mg/ml amsacrine alone (P<0.001,Wilcoxon signed-rank
test). The solid line represents equal extent of cell death with
amsacrine±PTK787/ZK 222584, whereas the dashed line represents
20% increase in cell death with addition of PTK787/ZK 222584. The
samples above the dashed line achieved an increase in cell death of
more than 20% when treated with 25mmol/l PTK787/ZK 222584
added to 1mg/ml amsacrine; 18 of the 29 samples showed an increase
in cell death of more than 20%.
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42 patients, despite continuous therapy, a strong in-
creased blast count was found [38]. Poor oral bioavail-
ability might be a reason for these results [25].
Interestingly, in this particular study, patients with
AML blasts expressing high levels of VEGF had a
significantly higher response rate than patients with low
VEGF expression.
Furthermore, a phase 1 study of SU11248, a receptor
tyrosine kinase inhibitor of c-kit, FLT3, KDR (IC50
10 nmol/l) and PDGFR-b in the treatment of patients
with refractory or resistant AML, showed molecular and
clinical activity in AML [39]. The inhibitor induced
partial remissions of short duration.
Two phase 1 trials with PTK787/ZK 222584 treatment in
patients with advanced colorectal cancer show that
patients with stable disease for at least 2 months achieve
up to 40% tumor regression [40]. The first results from a
phase 3 study in patients with metastatic adenocarcinoma
of the colon or rectum demonstrate that patients who
receive a combination of PTK787/ZK 222584 with a
chemotherapy regimen had a 17% reduction in the risk of
disease progression, compared with the outcome of
chemotherapy treatment alone [41]. Further analyses on
the data, including information on the overall survival
points, are expected soon.
In a phase 1 study of PTK787/ZK 222584 for the
treatment of primary refractory or relapsed AML, no
significant responses to treatment with PTK787/ZK
222584 were found. PTK787/ZK 222584 was also tested
in patients with secondary AML; monotherapy resulted in
stable disease for 10–14 months in two of the 35 patients.
Of the 17 patients treated with induction chemotherapy
and PTK787/ZK 222584, five achieved complete remis-
sion [42]. The potential clinical activity of PTK787/ZK
222584 in AML cell lines warrants further clinical
investigation.
It is demonstrated that single-agent VEGFR inhibitor
resulted in initial response, but of marginal duration.
These results suggest ongoing activation by other
signaling pathways. Recently, Kornblau et al. [43] showed
that activation of multiple signaling transduction path-
ways in AML patients is common. The prognosis of AML
patients worsens if more signaling transduction pathways
are activated. Therefore, targeting more signaling path-
ways byconventional chemotherapeutic drugs and/or
specialized tyrosine kinase inhibitors might be beneficial
for patients.
Interestingly, another clinical approach for the treatment
of AML used bevacizumab, an anti-VEGFA monoclonal
antibody, following chemotherapy [44]. Bevacizumab
targets extracellular VEGFA; thereby, its administration
prevents the stimulation resulting from VEGFA binding
to cell-surface receptor tyrosine kinases. In adults with
relapsed and refractory AMLs that were resistant to
traditional chemotherapy, combining cytotoxic chemo-
therapy with bevacizumab resulted in 33% complete
remission and a median disease-free survival of 7 months
in 35% of the patients. In summary, all these clinical
studies show that a therapeutic alternative is possible by
blocking VEGF/VEGFR signaling in the treatment of


























































Interaction data between the vascular endothelial growth factor receptor (VEGFR) inhibitor PTK787/ZK 222584 (PTK) and amsacrine for
primary acute myeloid leukemia blasts (n=6). (a) Three-dimensional (3D) plots presenting the raw data in terms of survival and logits for patient
samples. (b) 3D plots presenting a predicted model for logits and survival demonstrated for patient samples. The vertical axes in these figures
represent the (predicted) survival of the patient samples, estimated at different concentrations of both drugs (horizontal axes). Increasing the
concentration of one or both drugs results in a decrease of survival. (c) An isobole of the patient samples containing lines (shown as 0.3–0.7)
that represent the drug combinations at which 30, 40, 50, 60 or 70% of cell survival will be achieved. All three figures point out that the concentration
of amsacrine can be lowered and replaced by a dose of the VEGFR inhibitor, PTK787/ZK 222584, to achieve the same cell-death percentage.
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An internal and external autocrine VEGF/VEGFR path-
way is demonstrated to regulate VEGFR signaling
[45,46]. External/paracrine VEGF stimulation of hema-
topoietic stem cells (HSCs) did not result in survival or
proliferation; however, blocking the internal loop with
intracellularly acting inhibitors of VEGFR dramatically
reduced colony formation by HSCs, demonstrating the
importance of a VEGF/VEGFR internal/autocrine loop in
these cells. In contrast, in AML patient samples and
leukemic cell lines, it has been shown that treatment
with an external blocker results in a shift in KDR
localization from the nucleus to the surface of the cell,
suggesting that VEGF needs to be exported to internalize
KDR and activate signaling pathways. Moreover, internal
and external inhibitors exerted their effect via distinct
mechanisms, the internal having the strongest proapop-
totic effects by affecting the mitogen-activated protein
kinase/extracellular signal-related kinase (ERK) and the
PI3K/protein kinase B (Akt) pathways. Santos and Dias
also found that cells treated with both the internal and
external VEGF/KDR blockers in vitro undergo cell death
by apoptosis, to an even more significant extent than
those treated with either drug alone. Another interesting
difference in these studies is that KDR is thought to be
the main receptor for leukemic cell growth and cell
survival, whereas stimulation of both FLT1 and KDR can
rescue survival of VEGF-deficient HSCs. PTK787/ZK
222584 exerts its effect on KDR and, to a lesser extent,
on FLT1, but targeting both the internal and external
pathways might induce even more cell death.
In this study, we show that combined use of PTK787/ZK
222584 and amsacrine results in cell death and that, in a
combination strategy, a low dose of amsacrine combined
with PTK787/ZK 222584 can result in cell-death
percentages in vitro identical to those from a high dose
of amsacrine alone. Whether identical results will be
obtained in vivo remains to be investigated. In vivo,
VEGF/VEGFR signaling results in autocrine effects not
only in AML cells, but also in the surrounding tissues. For
instance, VEGFR inhibitors might inhibit paracrine
effects, in which VEGFR stimulation of stromal bone
marrow cells results in interleukin-6 and granulocyte
colony-stimulating factor known to be potential AML
growth factors [47]. Moreover, endocrine effects by which
VEGF induces new vessel formation can be inhibited, a
crucial prerequisite in tumor growth [48].
Amsacrine is a DNA topoisomerase inhibitor; DNA
topoisomerase inhibitors have been shown to transacti-
vate the VEGF promoter, resulting in the expression of
VEGF. It is known from literature that topoisomerase
inhibitors can cause treatment-related AML because
these drugs induce chromosomal breakage [49]. More-
over, a number of chemotherapeutic agents, such as
amsacrine, are also known for their cardiotoxicity [50]. To
reduce the risk and the complications of long-term
effects, it would be better to find a treatment strategy
in which the doses of such chemotherapeutic drugs, as for
instance amsacrine, can be at least lowered.
Acknowledgement
This work was supported by a grant from the ‘Dutch
Cancer Society’ to E.S.J.M. de B. (3661).
References
1 Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al.
The importance of diagnostic cytogenetics on outcome in AML: analysis of
1,612 patients entered into the MRCAML 10 trial. The Medical Research
Council Adult and Children’s Leukaemia Working Parties. Blood 1998;
92:2322–2333.
2 Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al.
The predictive value of hierarchical cytogenetic classification in older adults
with acute myeloid leukemia (AML): analysis of 1065 patients entered into
the United Kingdom Medical Research Council AML11 trial. Blood 2001;
98:1312–1320.
3 Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al.
Pretreatment cytogenetic abnormalities are predictive of induction success,
cumulative incidence of relapse, and overall survival in adult patients with de
novo acute myeloid leukemia: results from Cancer and Leukemia Group B
(CALGB 8461). Blood 2002; 100:4325–4336.
4 De Bont ES, Rosati S, Jacobs S, Kamps WA, Vellenga E. Increased
bone marrow vascularization in patients with acute myeloid leukaemia:
a possible role for vascular endothelial growth factor. Br J Haematol
2001; 113:296–304.
5 Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, et al.
Cellular vascular endothelial growth factor is a predictor of outcome in
patients with acute myeloid leukemia. Blood 1999; 94:3717–3721.
6 Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular
endothelial growth factor is a secreted angiogenic mitogen. Science 1989;
246:1306–1309.
7 Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular
endothelial growth factor family: identification of a fourth molecular species
and characterization of alternative splicing of RNA. Mol Endocrinol 1991;
5:1806–1814.
8 Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, et al. Vascular
endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases
VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci
U S A 1998; 95:548–553.
9 Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, et al. A novel
vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-
3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15:1751.
10 Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG,
Ziche M, et al. A novel vascular endothelial growth factor encoded by Orf
virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2
(KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 1999;
18:363–374.
11 Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, et al.
Vascular endothelial growth factor B, a novel growth factor for endothelial
cells. Proc Natl Acad Sci U S A 1996; 93:2576–2581.
12 Junqueira de Azevedo IL, Farsky SH, Oliveira ML, Ho PL. Molecular cloning
and expression of a functional snake venom vascular endothelium growth
factor (VEGF) from the Bothrops insularis pit viper. A new member of the
VEGF family of proteins. J Biol Chem 2001; 43:39836–39842.
13 De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The
fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
Science 1992; 255:989–991.
14 Galland F, Karamysheva A, Mattei MG, Rosnet O, Marchetto S, Birnbaum D.
Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase
gene. Genomics 1992; 13:475–478.
15 Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC,
Gospodarowicz D, et al. Identification of the KDR tyrosine kinase as a
receptor for vascular endothelial cell growth factor. Biochem Biophys Res
Commun 1992; 187:1579–1586.
16 Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD.
Neuropilin is a semaphorin III receptor. Cell 1997; 90:753–762.
17 Chen H, Chedotal A, He Z, Goodman CS, Tessier-Lavigne M. Neuropilin-2,
a novel member of the neuropilin family, is a high affinity receptor for the
semaphorins Sema E and Sema IV but not Sema III. Neuron 1997; 19:
547–559.
AML cell death induced by combination therapy Weidenaar et al. 53
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
18 Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is
expressed by endothelial and tumor cells as an isoform-specific receptor for
vascular endothelial growth factor. Cell 1998; 92:735–745.
19 Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML,
et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient
mice. Nature 1995; 376:62–66.
20 Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular
endothelial growth factor and its receptors in hematopoietic malignancies.
Cancer Res 1999; 59:728–733.
21 Weber-Nordt RM, Mertelsmann R, Finke J. The JAK-STAT pathway: signal
transduction involved in proliferation, differentiation and transformation.
Leuk Lymphoma 1998; 28:459–467.
22 Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/Akt is constitutively
active in primary acute myeloid leukaemia cells and regulates survival and
chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia
2005; 19:586–594.
23 Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase
cascades. Adv Cancer Res 1998; 74:49–139.
24 Dias S, Choy M, Alitalo K, Rafii S. Vascular endothelial growth factor
(VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell
proliferation, survival, and resistance to chemotherapy. Blood 2002;
99:2179–2184.
25 Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/
ZK 222584, a novel and potent inhibitor of vascular endothelial growth
factor receptor tyrosine kinases, impairs vascular endothelial growth factor-
induced responses and tumor growth after oral administration. Cancer Res
2000; 60:2178–2189.
26 Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR,
et al. Proposed revised criteria for the classification of acute myeloid
leukemia. A report of the French–American–British Cooperative Group.
Ann Intern Med 1985; 103:620–625.
27 Dokter WH, Tuyt L, Sierdsema SJ, Esselink MT, Vellenga E. The spontaneous
expression of interleukin-1 beta and interleukin-6 is associated with
spontaneous expression of AP-1 and NF-kappa B transcription factor in
acute myeloblastic leukemia cells. Leukemia 1995; 9:425–432.
28 Zwaan CM, Kaspers GJ, Pieters R, Ramakers-van Woerden NL, den Boer
ML, Wunsche R, et al. Cellular drug resistance profiles in childhood acute
myeloid leukemia: differences between FAB types and comparison with
acute lymphoblastic leukemia. Blood 2000; 96:2879–2886.
29 Pinheiro J, Bates D. Mixed-effects models in S and S-PLUS. Berlin:
Springer; 2000.
30 Padro T, Bieker R, Ruiz S, Steins M, Retzlaff S, Burger H, et al.
Overexpression of vascular endothelial growth factor (VEGF) and its cellular
receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid
leukemia. Leukemia 2002; 16:1302–1310.
31 Ria R, Vacca A, Russo F, Cirulli T, Massaia M, Tosi P, et al. A VEGF-
dependent autocrine loop mediates proliferation and capillarogenesis in
bone marrow endothelial cells of patients with multiple myeloma. Thromb
Haemost 2004; 92:1438–1445.
32 Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, et al.
Overproduction of VEGF concomitantly expressed with its receptors
promotes growth and survival of melanoma cells through MAPK and PI3K
signaling. J Invest Dermatol 2004; 123:1151–1161.
33 Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, et al. Autocrine
stimulation of VEGFR-2 activates human leukemic cell growth and migration.
J Clin Invest 2000; 106:511–521.
34 Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak
S, et al. Identification of mTOR as a novel bifunctional target in chronic
myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive
effects of rapamycin in leukemic cells. FASEB J 2005; 19:960–962.
35 Armstrong E, Kastury K, Aprelikova O, Bullrich F, Nezelof C, Gogusev J, et al.
FLT4 receptor tyrosine kinase gene mapping to chromosome band 5q35 in
relation to the t(2;5), t(5;6), and t(3;5) translocations. Genes Chromosomes
Cancer 1993; 7:144–151.
36 Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM. The
antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the
SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute
myeloid leukemia blasts. Blood 2001; 97:1413–1421.
37 Spiekermann K, Faber F, Voswinckel R, Hiddemann W. The protein tyrosine
kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting
and induces growth arrest and apoptosis by inhibition of c-kit in AML cells.
Exp Hematol 2002; 30:767–773.
38 Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, et al.
A phase 2 clinical study of SU5416 in patients with refractory acute
myeloid leukemia. Blood 2003; 102:2763–2767.
39 Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O’Farrell AM,
et al. A phase 1 study of SU11248 in the treatment of patients with
refractory or resistant acute myeloid leukemia (AML) or not amenable to
conventional therapy for the disease. Blood 2005; 105:986–993.
40 Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L,
et al. Soluble markers for the assessment of biological activity with
PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor
receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced
colorectal cancer from two phase I trials. Ann Oncol 2005; 16:
558–565.
41 Hecht JR, Trarbach T, Jaeger E, Hainsworth J, Wolff R, Lloyd K, et al. A
randomized, double-blind, placebo-controlled, phase III study in patients
(Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-
line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK
222584 or placebo (CONFIRM-1). J Clin Oncol 2005; 23:LBA3.
42 Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, et al. phase I
study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor
inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic
syndrome. Leukemia 2006; 6:952–957.
43 Kornblau SM,Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, et al.
Simultaneous activation of multiple signal transduction pathways confers
poor prognosis in acute myelogenous leukemia. Blood 2006; 108:
2358–2365.
44 Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, et al. Targeting
vascular endothelial growth factor for relapsed and refractory adult
acute myelogenous leukemias: therapy with sequential 1-beta-D-
arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res
2004; 10:3577–3585.
45 Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops
regulate survival of subsets of acute leukemia through distinct signaling
pathways. Blood 2004; 103:3883–3889.
46 Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, et al.
VEGF regulates haematopoietic stem cell survival by an internal autocrine
loop mechanism. Nature 2002; 417:954–958.
47 Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y,
et al. Vascular endothelial cell growth factor is an autocrine promoter of
abnormal localized immature myeloid precursors and leukemia progenitor
formation in myelodysplastic syndromes. Blood 2001; 97:1427–1434.
48 Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med
1971; 285:1182–1186.
49 Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs.
Biochim Biophys Acta 1998; 1400:233–255.
50 Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of
cancer chemotherapy: implications for children. Paediatr Drugs 2005;
7:187–202.
54 Anti-Cancer Drugs 2008, Vol 19 No 1
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
